concentrate of proteolytic enzymes enriched in bromelain

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for NexoBrid. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for NexoBrid.

This EPAR was last updated on 25/01/2023

Authorisation details

Product details
Agency product number
Active substance
proteolytic enzymes enriched in bromelain
International non-proprietary name (INN) or common name
concentrate of proteolytic enzymes enriched in bromelain
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
MediWound Germany GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim

Product information

24/01/2023 NexoBrid - EMEA/H/C/002246 - IAIN/0060

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Preparations for treatment of wounds and ulcers

Therapeutic indication

NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating